Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

19.30
-0.0800-0.41%
Volume:3.66M
Turnover:70.88M
Market Cap:1.90B
PE:-3.31
High:19.77
Open:19.48
Low:19.13
Close:19.38
52wk High:42.37
52wk Low:18.29
Shares:98.32M
Float Shares:94.49M
Volume Ratio:1.58
T/O Rate:3.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8316
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-22.03%
PB:-23.72
PE(LYR):-3.31

Loading ...

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

Dow Jones
·
Dec 30, 2025

Top Midday Stories: DigitalBridge to Be Acquired by SoftBank; Ultragenyx's Brittle Bone Disease Drug Studies Miss Primary Endpoints

MT Newswires Live
·
Dec 30, 2025

Wedbush Adjusts Price Target on Ultragenyx Pharmaceutical to $23 From $35, Maintains Neutral Rating

MT Newswires Live
·
Dec 30, 2025

Ultragenyx's Bone Disease Drug Fails to Improve Fracture Rate in Late-Stage Trials

Reuters
·
Dec 29, 2025

Ultragenyx-Mereo Bone Drug Trial Disappoints, Stocks Hit 52-Week Lows

Benzinga_recent_news
·
Dec 29, 2025

Update: Ultragenyx Shares Fall After Brittle Bone Disease Studies Fail to Achieve Primary Endpoints

MT Newswires Live
·
Dec 29, 2025

US Stock Alert | Ultragenyx Pharmaceutical (RARE.US) Plummets Over 42% Pre-Market After Late-Stage Trial Failure for Investigational Genetic Bone Disease Drug

Stock News
·
Dec 29, 2025

Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Benzinga_recent_news
·
Dec 29, 2025

Ultragenyx Pharma Shares Fall 42.6% Premarket After Bone Disease Drug Fails in Late-Stage Trials

THOMSON REUTERS
·
Dec 29, 2025

Ultragenyx Pharmaceutical Shares Halted, Pending Material News Release

MT Newswires Live
·
Dec 29, 2025

Ultragenyx Setrusumab Fails to Meet Primary Fracture Reduction Endpoint in Phase 3 Osteogenesis Imperfecta Trials

Reuters
·
Dec 29, 2025

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (Ux143) in Osteogenesis Imperfecta

THOMSON REUTERS
·
Dec 29, 2025

Ultragenyx Pharmaceutical Inc - Studies Show Improvements in Bone Mineral Density

THOMSON REUTERS
·
Dec 29, 2025

Ultragenyx Pharmaceutical Inc - to Implement Significant Expense Reductions

THOMSON REUTERS
·
Dec 29, 2025

Ultragenyx Pharmaceutical Inc - Phase 3 Studies Fail to Meet Primary Endpoint

THOMSON REUTERS
·
Dec 29, 2025

12 Days of Christmas? 12 Stocks That Are Gifts for 2026

Dow Jones
·
Dec 25, 2025

Ultragenyx Grants 13,144 Restricted Stock Units to New Hires

Reuters
·
Dec 20, 2025

Ultragenyx CFO Howard Horn Reports Sale of Common Shares

Reuters
·
Dec 12, 2025

Ultragenyx Pharmaceutical (RARE): Evaluating Valuation After Analyst Commentary on Setrusumab Progress and Growth Outlook

Simply Wall St.
·
Nov 30, 2025

Ultragenyx Pharmaceutical to Participate in Upcoming Investor Conferences

Reuters
·
Nov 25, 2025